# Zymeworks Announces Acquisition of Theravance Biopharma and YUPELRI for COPD

> ma · REPORTED · 2026-07-01

Zymeworks signed a definitive agreement to acquire Theravance Biopharma, adding YUPELRI (revefenacin), the first and only once-daily nebulized LAMA approved for COPD maintenance, to its commercial portfolio alongside its existing oncology assets. The deal is intended to generate near-term revenue and broaden Zymeworks' commercial footprint.

About Zymeworks: Zymeworks is a clinical-stage biopharmaceutical company developing multi-specific biotherapeutics for oncology and other serious diseases, with its lead commercial asset Ziihera (zanidatamab-hrii) for HER2-positive cancers.

- Company: Zymeworks
- Sector: therapeutics
- Primary source: https://www.delveinsight.com/blog/pharma-news-for-zymeworks-ipsen-viridian

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.